Rapport Therapeutics (NASDAQ:RAPP) Stock: Insider Wendy Young Purchases 3,789 Shares

Key Points

• Director Wendy Young purchased 3,789 Rapport Therapeutics shares at an average of $26.39, investing nearly $100,000 and increasing her stake by 39.88% to 13,289 shares.
• RAPP shares rose 5.9% to $26.53, while analysts maintained a broadly bullish outlook with a consensus “Buy” rating and a $68.36 price target. Institutional investors have also recently established or increased positions.
• Rapport’s lead drug candidate, RAP-219, is advancing toward Phase 3 after positive Phase 2 bipolar-mania results, though the company remains unprofitable and faces typical biotech risks including clinical execution, regulatory approval, and funding needs.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) Director Wendy Young bought 3,789 shares of the firm's stock in a transaction dated Thursday, October 22nd. The shares were acquired at an average price of $26.39 per share, with a total value of $99,991.71. Following the purchase, the director directly owned 13,289 shares of the company's stock, valued at approximately $350,696.71. This trade represents a 39.88% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link.

Rapport Therapeutics Trading Up 5.9%

Shares of NASDAQ RAPP traded up $1.47 during midday trading on Thursday, reaching $26.53. 1,453,606 shares of the company were exchanged, compared to its average volume of 407,078. Rapport Therapeutics, Inc. has a 1 year low of $23.75 and a 1 year high of $52.93. The stock has a fifty day simple moving average of $39.86 and a 200 day simple moving average of $39.07. The stock has a market cap of $1.27 billion, a P/E ratio of -8.73 and a beta of 1.22.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.07). As a group, analysts forecast that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

RAPP has been the topic of a number of analyst reports. Wells Fargo & Company lowered their price objective on shares of Rapport Therapeutics from $51.00 to $50.00 and set an "overweight" rating on the stock in a research report on Wednesday. TD Cowen restated a "buy" rating on shares of Rapport Therapeutics in a research report on Tuesday. Wolfe Research began coverage on shares of Rapport Therapeutics in a research note on Thursday, October 15th. They issued an "outperform" rating and a $50.00 target price for the company. UBS Group started coverage on shares of Rapport Therapeutics in a report on Thursday, October 15th. They issued a "buy" rating and a $71.00 target price on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $66.00 price target on shares of Rapport Therapeutics in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $68.36.

Hedge Funds Weigh In On Rapport Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Engineers Gate Manager LP acquired a new position in shares of Rapport Therapeutics during the 2nd quarter worth $888,000. Wellington Management Group LLP lifted its stake in shares of Rapport Therapeutics by 11.2% in the second quarter. Wellington Management Group LLP now owns 86,988 shares of the company's stock valued at $3,625,000 after purchasing an additional 8,757 shares during the period. Artia Global Partners LP acquired a new stake in shares of Rapport Therapeutics in the second quarter valued at about $5,772,000. Bank of America Corp DE acquired a new stake in shares of Rapport Therapeutics in the second quarter valued at about $3,170,000. Finally, Jupiter Topco LLC purchased a new stake in Rapport Therapeutics during the second quarter worth about $574,000.

Key Headlines Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 is advancing to Phase 3. Rapport said the drug met both Phase 2 endpoints in bipolar mania, producing statistically significant placebo-adjusted improvements in manic symptoms and overall illness severity. The results strengthen the potential value of RAP-219 and expand its development opportunity beyond epilepsy. Rapport plans Phase III bipolar mania trials
• Positive Sentiment: Analysts continue to raise or maintain bullish targets. JonesTrading increased its price target from $50 to $82 and maintained a Buy rating. BTIG Research also raised its target, while HC Wainwright reaffirmed its Buy rating. Raymond James recently set an $86 target and maintained Strong Buy. The analyst activity suggests Wall Street sees substantial upside if RAP-219 succeeds in later-stage development. BTIG Research price target update HC Wainwright rating update
• Positive Sentiment: CFO Troy Ignelzi bought 5,500 shares for $143,550. The purchase increased his direct holdings by 55% to 15,500 shares, a potentially supportive signal of management confidence. SEC insider ownership filing
• Neutral Sentiment: The clinical results move RAP-219 toward Phase 3 but do not eliminate biotechnology risks, including trial execution, regulatory approval, funding needs, and eventual commercialization.
• Negative Sentiment: Some coverage characterized the trial outcome as narrower than investors initially hoped. Rapport also remains unprofitable, recently reporting quarterly EPS below consensus, which could limit gains if future clinical or financial results disappoint. Rapport bipolar data analysis

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company's approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport's lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.